




MEDICINAL PRODUCTS 2022

MYRIAD GENETICS INC
Rank 15 of 51





MEDICINAL PRODUCTS 2022

MYRIAD GENETICS INC Rank 15 of 51



The relative strengths and weaknesses of MYRIAD GENETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MYRIAD GENETICS INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 45% points. The greatest weakness of MYRIAD GENETICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 8.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 95%, being 108% points above the market average of -14%.

Input Variable	Value in 1000 USD
Assets, Current	484,800
Assets, Non-Current	149,100
General and Administrative Expense	537,800
Goodwill	643,300
Liabilities, Current	240,100
Liabilities, Non-Current	84,900
Other Assets	0
Other Compr. Net Income	-2,800
Other Expenses	231,500
Other Liabilities	27,900
Other Net Income	133,400
Other Revenues	690,600
Property, Plant and Equipment, Net	43,500
Research and Development	81,900

Output Variable	Value in 1000 USD
Liabilities	352,900
Assets	1,320,700
Expenses	851,200
Revenues	690,600
Stockholders Equity	967,800
Net Income	-27,200
Comprehensive Net Income	-28,600
Economic Capital Ratio	95%